A survey in eight European countries, including 13 hospitals, of vancomycin-resistant enterococci (VRE) in at-risk hospital wards (such as the ICU and the haematology ward) was performed in 2001, and the in vitro susceptibility of the isolates ramoplanin and other drugs was tested. A total of 1314 non-duplicate clinical enterococcal isolates were collected, and 38 (2.9%) were vancomycin resistant: 27 Enterococcus faecium and 11 Enterococcus faecalis; 35 VanA and three VanB phenotypes. Rates of VRE among clinical enterococcal isolates varied between 0 and 1.7% for the participating countries, except the UK (10.4%) and Italy (19.6%). One hundred and twenty-three (3.5%) VRE were found among 3499 stool samples tested for the presence of these organisms: 111 (3.2%) E. faecium and 12 (0.3%) E. faecalis; 114 (3.3%) VanA and nine (0.3%) VanB phenotypes. Rates of intestinal colonization with VRE varied between 0 and 1.2% for the participating countries, except Italy (7.5%) and the UK (32.6%). In vitro susceptibility testing showed that the Italian and UK VRE are multi-resistant (including resistance to ampicillin and high-level resistance to gentamicin and streptomycin), and that ramoplanin was active against all strains of VRE, with an MIC 90 of 0.5 mg/L for clinical isolates. Pulsed-field gel electrophoresis showed that the high prevalence of VRE in the Italian and UK centres was related to the monoclonal emergence and spread of three centre-specific clones. This survey suggests that in some centres in Europe, a similar situation may be encountered to that in the USA (monoclonal spread of multi-resistant VRE in at-risk wards).
Introduction
Enterococci form part of the normal host flora of both the human and animal gastrointestinal tracts. Their association as aetiological agents of bacteraemia, endocarditis and urinary tract infections in humans is well documented. 1 In the past decade, these organisms have become notorious nosocomial pathogens, in spite of their limited virulence. This is related to their resistance to several antimicrobial agents, and this resistance can be intrinsic (low-level to penicillin, cephalosporins and aminoglycosides) as well as acquired (resistance to glycopeptides and high-level resistance to aminoglycosides). Indeed, enterococci can rapidly acquire and disseminate resistance genes. Glycopeptide-resistant enterococci, more commonly designated vancomycin-resistant enterococci (VRE), have attracted much interest. They have emerged as an important cause of hospital-acquired infection, particularly in the USA: recent reports suggest that almost a quarter of enterococci isolated from intensive care patients in the USA are VRE. 2, 3 In Europe, however, vancomycin-resistant Enterococcus faecium strains have been isolated mostly from farm animals, 4,5 meat 5, 6 and environmental sources. 6, 7 There is a need for surveillance of VRE to address the evolving epidemiology of these organisms, and for new therapies and management concepts to address increased resistance to many antimicrobials. This article discusses a recent survey conducted in eight European Union countries. The objective of this multicentre study was to collect updated data on the prevalence of VRE among clinical isolates and to determine 
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Susceptibility testing
Enterococci were tested for glycopeptide resistance by plating on screening agar supplemented with 6 mg/L vancomycin. For all strains that grew on this medium, MICs of vancomycin and teicoplanin were determined by Etest. Each laboratory received a panel of control strains expressing different phenotypes of glycopeptide resistance. E. faecalis susceptible to vancomycin were not studied further; all strains other than E. faecalis, irrespective of their glycopeptide resistance, were collected and sent to Vicuron Pharmaceuticals for susceptibility testing by microdilution according to NCCLS criteria. 9 MICs were determined for the following: ampicillin (Sigma Chemical Co., St Louis, MO, USA), gentamicin (Sigma), streptomycin (Sigma), vancomycin (Sigma), teicoplanin (Gruppo; Lepetit, Milan, Italy), ramoplanin (Vicuron Pharmaceuticals), quinupristin/dalfopristin (Synercid; commercial preparation of Aventis, Italia) and linezolid (Zyvox; commercial preparation of Pharmacia, Italia).
Genotypic testing
The vanA, vanB, vanC1 and vanC2 genes were determined as described elsewhere. 10 The clonal distribution among all vancomycin-resistant E. faecium strains was studied by pulsedfield gel electrophoresis (PFGE) as described by Descheemaeker et al. 11 In brief, bacterial cells on an agar medium were embedded in low-melting-temperature agarose (Bio-Rad Laboratories, Nazareth, Belgium). After cell wall and protein digestion, the plugs were digested with 30 U of SmaI (MBI Fermentas, St Leon-Rot, Germany) at 25°C for 24 h. PFGE was performed with a 1% agarose gel using a CHEF Mapper apparatus (Bio-Rad Laboratories) in 0.5× Tris-borate-EDTA (TBE) buffer at 14°C at 6 V/cm. For separation, a linearly ramped switching time of 5-35 s was applied for 24 h. After the gel was stained with ethidium bromide, the image was digitized on a Gel Doc 1000 System (Bio-Rad Laboratories). The similarity between PFGE patterns was evaluated by use of Dice coefficient and visually by a maximum of three clearly visible bands.
Results
Clinical isolates
A total of 1314 non-duplicate clinical enterococcal isolates were collected, and 38 (2.9%) were confirmed as VRE ( Table 1) . The strains were identified as 27 (2.1%) E. faecium and 11 (0.8%) E. faecalis. Tables 2 and 3 , respectively. Half of the VRE isolates were obtained from patients admitted to the ICU, and blood was the main source of VRE (31.6%).
Faecal samples
One hundred and twenty-three (3.5%) VRE were found among the 3499 stool samples tested: 111 (3.2%) E. faecium and 12 (0.3 %) E. faecalis; 114 (3.3%) and nine (0.3%) were of the VanA and VanB phenotypes, respectively ( Table 1) . The rates of intestinal colonization with VanA and VanB types of VRE among the countries varied significantly: rates were 0% for Austria, 0.3% for France, 0.4% for Spain, 0.6% for Belgium, 1.2% for Germany, 7.5% for Italy and 32.6% for the UK (Figure 2 ). Most VRE isolates were collected from patients admitted to the ICU (42.3%), oncology/haematology/bone marrow transplantation wards (31.5%) and medical wards (14.4%).
Antimicrobial susceptibility testing
The in vitro susceptibility of 26 clinical isolates and 108 faecal VanA enterococcal isolates is shown in Table 4 . Clearly, these isolates are highly resistant to most antibiotics tested, includ- ing ampicillin, gentamicin and streptomycin. Some signs of early resistance to the newer agent quinupristin/dalfopristin can also be detected. Ramoplanin was active against all strains of VRE, with an MIC 90 of 0.5 mg/L for clinical isolates.
PFGE typing of vancomycin-resistant E. faecium
All 138 VanA and VanB phenotypes of E. faecium were analysed by PFGE, and 52 PFGE groups were found as defined by Tenover et al. 12 The patterns of the isolates collected in the centres in Belgium, France, Germany and Spain were clearly unrelated. As mentioned previously, three Italian centres participated in the study. The isolates from the first of these were unrelated. PFGE grouping of the vancomycin-resistant E. faecium from the second and third centres is shown in Tables 5 and 6 . In the second Italian centre, referred to as centre D, 58 VRE were collected, all VanA phenotype; these included 13 clinical isolates (of which six were blood isolates) and 45 VRE from faecal samples (Table 5) . Fifty-seven of the 58 VRE were isolated from patients admitted to the ICU. The 58 VRE belonged to 11 PFGE groups and one group (11) represented more than half of the VRE isolated in this centre. All isolates were highly resistant to ampicillin, gentamicin and streptomycin. In the third Italian centre (centre F) 36 VRE were collected, all VanA phenotype, which included four clinical isolates (of which two were blood isolates) and 32 VRE isolated from faecal samples (Table 6 ). Among the 36 VRE, 17 and 14 were isolated from patients admitted to the medical and haematology wards, respectively. The 36 VRE belonged to nine PFGE groups and one group (26) represented half of the VRE isolated in this centre. All isolates were highly resistant to ampicillin, gentamicin and streptomycin. In the only UK centre (centre A) 32 VRE were collected, 28 VanA and four VanB phenotype; these included eight clinical isolates (of which three were blood isolates) and 24 isolates from faecal samples ( Table 7) . Twenty-two isolates were from patients admitted to the haematology ward. The isolates belonged to 20 PFGE groups and one group (49) represented about one-third of the VRE isolated in this centre. All isolates were resistant to ampicillin, and 23 and 25 were resistant to gentamicin and streptomycin, respectively. Isolates within the large haematology cluster were, however, resistant to all three antibiotics.
Discussion
In Europe, colonization with VRE appears to be endemic in healthy people and farm animals; outbreaks occur occasionally. 13 European VRE of sporadic human origin, as well as animal isolates, are usually susceptible to many other antibiotics, such as ampicillin, gentamicin at high level and ciprofloxacin. Most outbreaks of VRE in Europe have occurred in nephrology and haematology wards, and they were frequently caused by highly polyclonal, vanA-positive E. faecium. In contrast to the USA, only a few outbreaks are reported in ICUs.
In most European hospitals participating in our ramoplanin surveillance study, infections caused by VRE and intestinal 
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colonization with these organisms remain very low. The prevalence of gastrointestinal colonization with VRE was found to be higher than the incidence of infection with these organisms. These data are in concordance with the results of other studies in Europe demonstrating that VRE may be distributed widely in the community. 5, 14, 15 We noticed, however, that in three centres in two countries, Italy and the UK, the prevalence of VRE among clinical and faecal isolates was surprisingly high, which was due largely to the clonal hospital spread of multi-resistant VanA phenotypes of E. faecium strains. These clones had spread particularly in the ICU and haematology wards and had caused bloodstream infections in the Italian centres. Although the high prevalence of VRE in haematology wards is not especially unusual, in our participating hospitals these high rates were due to clonal outbreaks of VanA phenotypes of E. faecium strains. The incidence of nosocomial infections with VRE in these three hospitals varied in accordance with the rate of VRE carriage in the gastrointestinal tract. Thus, in the Italian and UK participating hospitals, a similar situation to that in the USA was 13 The design of the study (only specimens from at-risk wards) may, however, overestimate the overall prevalence of VRE within a given hospital. Further investigations are warranted to monitor the emergence of these isolates, which show resistance to the glycopeptides, ampicillin and the aminoglycosides and signs of initial resistance to the recently approved agent quinupristin/ dalfopristin. A possibility that should be explored is whether the acquisition of particular virulence determinants in these European VRE favours either gastrointestinal colonization only on the one hand or the potential for invasive infection on the other. Geographical variation may be related to the presence of pathogenicity islands and antimicrobial resistance determinants. Several putative virulence properties have been identified in E. faecalis, including aggregation substance, haemolysin and gelatinase. 16 A gene encoding a putative enterococcal surface protein, esp, was recently identified in E. faecalis and E. faecium. [17] [18] [19] Its presence in E. faecium has been identified as a marker for a clone that has spread across continents. 20 Our data suggest that ampicillin-resistant E. faecium isolates selected under antibiotic pressure in hospitals can subsequently acquire esp. 16 These clones may have changed in ways that make them more likely to cause infection. Other potential virulence factors that have been identified in E. faecium include genes encoding gelatinase, lipases and hyaluronidase. [21] [22] [23] Although E. faecium has been considered a bacterium with low or questionable virulence, the increased number of nosocomial enterococcal infections, as well as the identification of potential virulence factors and resistance determinants, raises concern about the emergence and spread of certain clones. Whether the epidemiology in Europe-for example, in Italy and the UK-is changing rapidly, and whether we are evolving towards a situation that resembles that in the USA is uncertain. Clearly, surveillance studies are mandatory to carefully monitor changing trends in Europe. The VRE/ramoplanin European surveillance study has shown that ramoplanin is highly active against all strains of VRE with no reports of resistance thus far, and no evidence of crossresistance between ramoplanin and other classes of antimicrobials, including glycopeptides. Ramoplanin may have a role to play in the prevention of infection in VRE-colonized patients and in controlling the transmission of VRE and vancomycin resistance genes within a hospital.
